協和キリンの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2016/10/05 | 1,598 | 1,600 | 1,571 | 1,574 | -17 | -1.1% | 632,900 |
2016/10/04 | 1,597 | 1,598 | 1,576 | 1,591 | ±0 | ±0% | 792,700 |
2016/10/03 | 1,600 | 1,611 | 1,587 | 1,591 | +5 | +0.3% | 645,900 |
2016/09/30 | 1,579 | 1,592 | 1,553 | 1,586 | -13 | -0.8% | 1,041,200 |
2016/09/29 | 1,601 | 1,611 | 1,591 | 1,599 | +7 | +0.4% | 602,500 |
2016/09/28 | 1,603 | 1,612 | 1,580 | 1,592 | -30 | -1.8% | 588,600 |
2016/09/27 | 1,586 | 1,622 | 1,565 | 1,622 | +27 | +1.7% | 1,062,400 |
2016/09/26 | 1,613 | 1,620 | 1,589 | 1,595 | -35 | -2.1% | 898,900 |
2016/09/23 | 1,630 | 1,638 | 1,611 | 1,630 | +12 | +0.7% | 898,900 |
2016/09/21 | 1,590 | 1,619 | 1,553 | 1,618 | +41 | +2.6% | 1,253,000 |
2016/09/20 | 1,550 | 1,581 | 1,550 | 1,577 | -8 | -0.5% | 984,300 |
2016/09/16 | 1,564 | 1,587 | 1,557 | 1,585 | +37 | +2.4% | 869,200 |
2016/09/15 | 1,580 | 1,580 | 1,536 | 1,548 | -50 | -3.1% | 1,412,900 |
2016/09/14 | 1,581 | 1,611 | 1,575 | 1,598 | +17 | +1.1% | 927,400 |
2016/09/13 | 1,585 | 1,603 | 1,569 | 1,581 | +7 | +0.4% | 904,300 |
2016/09/12 | 1,561 | 1,586 | 1,553 | 1,574 | -1 | -0.1% | 945,800 |
2016/09/09 | 1,564 | 1,582 | 1,557 | 1,575 | -11 | -0.7% | 2,117,400 |
2016/09/08 | 1,596 | 1,599 | 1,566 | 1,586 | -4 | -0.3% | 1,130,000 |
2016/09/07 | 1,584 | 1,596 | 1,568 | 1,590 | ±0 | ±0% | 1,833,600 |
2016/09/06 | 1,542 | 1,598 | 1,537 | 1,590 | +79 | +5.2% | 2,747,000 |
2016/09/05 | 1,530 | 1,532 | 1,506 | 1,511 | -9 | -0.6% | 946,600 |
2016/09/02 | 1,512 | 1,542 | 1,510 | 1,520 | +30 | +2% | 1,731,400 |
2016/09/01 | 1,460 | 1,495 | 1,450 | 1,490 | +22 | +1.5% | 1,691,800 |
2016/08/31 | 1,466 | 1,477 | 1,448 | 1,468 | +3 | +0.2% | 1,236,700 |
2016/08/30 | 1,440 | 1,478 | 1,436 | 1,465 | +36 | +2.5% | 1,386,100 |
2016/08/29 | 1,436 | 1,442 | 1,412 | 1,429 | -3 | -0.2% | 1,856,300 |
2016/08/26 | 1,468 | 1,473 | 1,430 | 1,432 | -46 | -3.1% | 1,715,500 |
2016/08/25 | 1,490 | 1,497 | 1,466 | 1,478 | -28 | -1.9% | 1,800,200 |
2016/08/24 | 1,511 | 1,523 | 1,496 | 1,506 | -13 | -0.9% | 1,309,200 |
2016/08/23 | 1,465 | 1,539 | 1,465 | 1,519 | +41 | +2.8% | 1,484,800 |
2016/08/22 | 1,486 | 1,502 | 1,468 | 1,478 | ±0 | ±0% | 1,172,100 |
2016/08/19 | 1,507 | 1,514 | 1,465 | 1,478 | -29 | -1.9% | 1,972,100 |
2016/08/18 | 1,558 | 1,561 | 1,504 | 1,507 | -50 | -3.2% | 1,558,300 |
2016/08/17 | 1,564 | 1,569 | 1,541 | 1,557 | -26 | -1.6% | 1,470,800 |
2016/08/16 | 1,621 | 1,626 | 1,583 | 1,583 | -34 | -2.1% | 1,413,700 |
2016/08/15 | 1,633 | 1,634 | 1,614 | 1,617 | -37 | -2.2% | 664,500 |
2016/08/12 | 1,653 | 1,662 | 1,633 | 1,654 | +24 | +1.5% | 1,431,500 |
2016/08/10 | 1,639 | 1,648 | 1,617 | 1,630 | -22 | -1.3% | 1,409,200 |
2016/08/09 | 1,631 | 1,663 | 1,621 | 1,652 | -2 | -0.1% | 1,688,600 |
2016/08/08 | 1,675 | 1,687 | 1,637 | 1,654 | -10 | -0.6% | 823,300 |
2016/08/05 | 1,680 | 1,686 | 1,648 | 1,664 | -35 | -2.1% | 1,354,700 |
2016/08/04 | 1,711 | 1,721 | 1,688 | 1,699 | -1 | -0.1% | 1,779,300 |
2016/08/03 | 1,715 | 1,729 | 1,698 | 1,700 | -49 | -2.8% | 1,299,200 |
2016/08/02 | 1,741 | 1,772 | 1,730 | 1,749 | -15 | -0.9% | 1,091,600 |
2016/08/01 | 1,771 | 1,793 | 1,737 | 1,764 | -39 | -2.2% | 1,603,800 |
2016/07/29 | 1,782 | 1,813 | 1,763 | 1,803 | -8 | -0.4% | 1,990,700 |
2016/07/28 | 1,865 | 1,869 | 1,800 | 1,811 | -77 | -4.1% | 1,375,200 |
2016/07/27 | 1,920 | 1,926 | 1,884 | 1,888 | -28 | -1.5% | 1,211,100 |
2016/07/26 | 1,916 | 1,935 | 1,905 | 1,916 | -11 | -0.6% | 956,400 |
2016/07/25 | 1,909 | 1,954 | 1,893 | 1,927 | +24 | +1.3% | 1,124,500 |
2101~
2150
件表示中 / 3698件
類似銘柄と比較する
現在ご覧いただいている「協和キリン」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
協和キリン | 217,400円 | -3.5% | -11.3% | 2.76% | 19.97倍 | 1.34倍 |
|
キリン傘下。医薬品、バイオが主力。独自の抗体高活性化技術に強み。富士フイルムと提携 |
アステラス薬 | 135,300円 | +0.9% | +380.2% | 5.76% | 18.63倍 | 1.60倍 |
|
医薬品国内2位。開発技術起点の研究開発体制。前立腺がん薬が柱。遺伝子・細胞治療技術育成 |
塩野義 | 220,700円 | +20.9% | +10.6% | 2.99% | 10.43倍 | 1.38倍 |
|
抗HIV薬が大型製品に。感染症、疼痛・中枢神経領域に強み。米国に積極展開。欧州、アジア開拓 |
エーザイ | 388,100円 | +1.7% | -2.9% | 4.12% | 25.46倍 | 1.34倍 |
|
神経系、がん領域に強み。認知症薬は米バイオジェンと、抗がん薬では米メルクと国際協業推進 |
小野薬 | 150,100円 | +0.6% | +43.3% | 5.33% | 10.52倍 | 0.90倍 |
|
医療用医薬品専業の中堅。自社開発品多い。先駆的がん免疫阻害剤「オプジーボ」が成長牽引 |
市場注目の銘柄
チャート関連のコラム